Meridian Bioscience (VIVO) Stock Price, News & Analysis

Company Overview

Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.

Key Stats

• Today's Range: $33.97 to $33.97
• 50-Day Range: $33.00 to $33.97
• 52-Week Range: $20.35 to $34.38
• Volume: N/A
• Average Volume: 973,737 shs
• Market Capitalization: $1.50 billion
• P/E Ratio: 35.02
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VIVO Stock Analysis - Frequently Asked Questions

How were Meridian Bioscience's earnings last quarter?

Meridian Bioscience, Inc. (NASDAQ:VIVO) announced its quarterly earnings results on Friday, November, 12th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.03. The company earned $76.20 million during the quarter, compared to the consensus estimate of $68.40 million. Meridian Bioscience had a net margin of 12.70% and a trailing twelve-month return on equity of 16.74%.

Does Meridian Bioscience have any subsidiaries?

The following companies are subsidiaries of Meridian Bioscience: Exalenz Bioscience.

What other stocks do shareholders of Meridian Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Meridian Bioscience investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), PayPal (PYPL), Micron Technology (MU) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 11/12/2021
• Today: 7/14/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: Health Care Supplies
• Current Symbol: NASDAQ:VIVO
• CIK: 794172
• Web: www.meridianbioscience.com
• Phone: (513) 271-3700
• Fax: 513-271-3762
• Employees: 702
• Year Founded: 1977

Profitability

• EPS (Trailing Twelve Months): $0.97
• Trailing P/E Ratio: 35.02
• Forward P/E Ratio: 40.93
• P/E Growth: N/A
• Net Income: $42.46 million
• Net Margins: 12.70%
• Pretax Margin: 16.31%
• Return on Equity: 16.74%
• Return on Assets: 13.09%

Debt

• Debt-to-Equity Ratio: 0.07
• Current Ratio: 3.63
• Quick Ratio: 2.46

Sales & Book Value

• Annual Sales: $333.02 million
• Price / Sales: 4.49
• Cash Flow: $1.78 per share
• Price / Cash Flow: 19.13
• Book Value: $8.41 per share
• Price / Book: 4.04

Miscellaneous

• Outstanding Shares: 44,010,000
• Free Float: 42,996,000
• Market Cap: $1.50 billion
• Optionable: Optionable
• Beta: 0.23